[1] TRAN C,OUK S,CLEGG N,et al. Development of a second generation antiandrogen for treatment of advanced prostate cancer[J]. Science,2009,324(5928):787-790.[2] 刘子建. 恩杂鲁胺[J]. 中国药物化学杂志,2013,23(1):79.LIU Zi-jian. Enzalutamide[J]. Chinese Journal of Medicinal Chemistry,2013,23(1): 79. (in Chinese)[3] CHARLES LS,MICHAEL EJ,CHARLIE DC,et al. Diarylhydantoin Compounds:US,7709517[P].2010-05-04.[4] HOWARD L SCHER,KARIM FIZAZI,FRED SAAD,et al. Increased survival with enzalutamide in prostate after chemotherapy[OL]. N Engl Med:2012-8-15.[5] 王明超,程跃. 新型去势难治性前列腺癌治疗药物MDV3100研究简介[J]. 现代泌尿生殖肿瘤杂志,2013,5(6): 373-374. WANG Ming-chao,CHENG Yue. The new castration resistant prostate cancer treatment drug mdv3100 research profile[J]. J Contemp Urol Reprod Oncol,2013,5(6): 373-374.(in Chinese)[6] FOSSA SD,SLEE PH,Brausi M,et al. Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group[J]. J Clin Oncol,2001,19(1):62-71.[7] AKAZA H,HINOTSU S,USAMI M,et al. Study group for the combined androgen blockade therapy of prostate cancer combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3,double-blind,randomized study for survival[J]. Cancer,2009;115(15):3437-3445.[8] CRAWFORD E D,EISENBERGER M A,MCLEOD DG,et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma[J]. N Engl J Med, 1989,321(7):419-424.[9] CHEN CD,WELSBIE DS,TRAN C,et al. Molecular determinants of resistance to antiandrogen therapy[J]. Nat Med, 2004,10(1):33-39.[10] KOLVENBAG GJ,FURR BJ,BLACKLEDGE GR. Receptor affinity and potency of non-steroidal antiandrogens: translation of preclinical findings into clinical activity[J]. Prostate Cancer Prostatic Dis, 1998(6):307-314.[11] SCHER H I,BEER TM,HIGANO CS,et al; Prostate Cancer Foundation/Department of defense prostate cancer clinical trials consortium antitumour activityof MDV3100 in castration-resistant prostate cancer:a phase 1-2 study[J]. Lancet,2010,375(9724):1437-1446.[12] SCHER HI,FIZAZI K,SAAD F,et al. Increased survival with enzalutamide in prostate cancer after chemotherapy[J]. N Engl J Med,2012,367:1187-1197.[13] MARCIAN E D, DIANE M R, BESS W. Design, Synthesis, and Pharmacological Characterization of 4-[4,4-Dimethyl-3-(4-hydroxybutyl)-5-oxo-2-thioxo-1-imidazolidinyl]-2-iodobenzonitrile as a High-Affinity Nonsteroidal Androgen Receptor Ligand [J]. J Med Chem,2000, 43(17):3344-3347.[14] SAWYERS C,JUNG M,CHEN C,et al. Diarylhydantoin compounds:WO,2006124118 [P].2006-11-23. [15] SAWYERS C,JUNG M,CHEN C,et al. Diarylhydantoin compounds:CN,200680025545.1[P].2008-7-16.[16] JUNG M,YOO D,SAWYERS C,et al. Diarylhydantoin Compounds: EP,2397469A1 [P]. 2008-10-24.[17] JUNG M,YOO D,SAWYERS C,et al. Diarylthiohydantoin compounds:US,20070254933[P].2007?鄄11?鄄01.[18] WONG R,DOLMAN S J. Isothiocyanates from tosyl cholride mediated decomposition of in situ generated dithiocarbamic acid salts[J]. J Org Chem,2007,72(10): 3969-3971. [19] 徐德锋. 一种4-氨基-2-氟-N-甲基苯甲酰胺的制备方法: CN,103304439A[P]. 2013-09-18. XU De-feng. A method for Preparing 4-amino-2-fluoro-N-methylbenzamide:CN,103304439A[P]. 2013-09-18.(in Chinese)[20] 杜晓华,许响生,傅幼锋,等. 非硫光气法合成一些难合成的芳基异硫氰酸酯[J]. 农药,2004,43(2):78-79.DU Xiao-hua,XU Xiang-sheng,FU You-feng,et al. Overcoming aromatic isothiocyanate synthesis difficulties with a method avoiding use of thiophosgene[J]. Chinese Journal of Pesticides,2004,43(2):78-79.(in Chinese)[21] 宋丽君,王飏,李志裕,等. 雄激素受体拮抗剂MDV3100的合成研究[J]. 精细化工中间体,2012,42(1):34-36.SONG Li-jun,WANG Yang,LI Zhi-yu,et al. Synthesis of androgen receptor antagonists MDV3100[J]. Fine Chemical Intermediates,2012,42(1):34-36.(in Chinese) [22] JACOBSEN E J,TENBRINK R E,STELZER L S,et al. High-affinity partial agonist imidazo [1,5-a] quinoxaline amides,carbamates,and ureas at the gamma-aminobutyric acid A/benzodiazepine receptor complex[J]. J Med Chem,1996,39(1): 158-175. [23] OHCANDA J,STRICKLAND C L,BLASKOVICH M A,et al. Structure based design of imidazole-containing peptidomimetic inhibitors of protein farnesy Itransferase[J]. Org Biomol Chem,2006,4(3): 482-492. [24] MICHEAL E, SAMEDY O, DONGWON Y, et al. Structure activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer(CRPC)[J]. J Med Chem,2010,53(7): 2779-2796. [25] YOSHINO H,SATO H,TACHIBANA K,et al. Structure-activity relationships of bioisosteric replacement of the carboxylic acid in novel androgen receptor pure antagonists[J]. Bio Org Med Chem,2010,18(9): 3159-3168. [26] 汤普森A,兰伯森C,格林菲尔德S,等.合成二芳基乙内酰硫脲和二芳基乙内酰脲化合物的方法:CN,103108549[P].2013-05-15. THOMPSON A,LAMBERSON C,GREENFIELD S,et al. Processes for the synthesis of diarylthiohydantoin and diarylhydantoin compounds: CN,103108549[P].2013-05-15. (in Chinese) [27] 张霁,聂飚,张英俊. 有机合成在创新药物研发中的应用与进展[J]. 有机化学,2015,35,337-361.ZHANG Ji,NIE Biao,ZHANG Ying-jun. Application and progress of organic synthesis in the discovery of innovative drugs[J]. Chinese Journal of Organic Chemistry,2015,35,337-361. (in Chinese)[28] 阮诗文,严海艳,夏洪飞,等. 一种“一锅法”合成恩杂鲁胺的方法: CN104016924[P].2014-09-03.RUAN Shi-wen,YAN Hai-yan,XIA Hong-fei,et al. A method of one-pot synthesis of Enzalutamide: CN104016924[P]. 2014-09-03. (in Chinese) [29] 杭太俊,于治国,范国荣,等.药物分析[M]. 北京: 人民卫生出版社,2011. HANG Tai-jun,YU Zhi-guo,FAN Guo-rong,et al. Pharmaceutical analysis[M]. Beijing: People’s Medical Pubishing House,2011. (in Chinese)[30] 谢文成. 雄激素受体拮抗剂MDV3100的合成研究[D]. 济南:山东大学药学院,2014.XIE Weng-cheng. Synthesis study of MDV3100 as androgen receptor antagonists[D]. Jinan: School of Pharmaceutical Science,Shang dong Uiversity,2014.(in Chinese)[31] PEDDY V,BOGE R,MADIVADA L R. Enzalutamide polymorphic forms and its preparation: WO,2014041487A2[P]. 2014-03-20.[32] 杜焕达,罗瑾,叶鑫杰,等.恩杂鲁胺新晶型及其制备方法:CN,104356068A[P].2015-02-18DU Huan-da,LUO Jin,YE Xin-jie,et al. Enzalutamide new crystal form and preparation method thereof:CN,104356068A[P].2015-02-18.(in Chinese)[33] 崔福德,吕万良,陆彬,等.药剂学[M]. 北京:人民卫生出版社,2008.CUI FU-de,LV WAN-liang,LU Bin,et al. Pharmaceutics[M]. Bei jing: People’s Medical Pubishing House,2008. (in Chinese)[34] LORENZ DA,KONAGURTHU S,WALD R J,et al. Formulation of enzalutamide:WO,2014043208A1[P].2014-03-20.[35] DOUGLAS A L,SANJAY K,RANDY JW,et al. Formulations of Enzalutamide:US,20140100256[P].2014-04-10.[36] DOUGLAS A L,SANJAY K,RANDY JW,et al. Formulations of enzalutamide:US,2014179749[P].2014-07-26.[37] DOUGLAS A L,SANJAY K,RANDY JW,et al. Formulations of enzalutamide:US,2014378517[P].2014-12-25.[38] DOUGLAS A L,SANJAY K,RANDY JW,et al. Formulations of enzalutamide:CA,2884795[P].2014-03-20.[39] JOELLE EA,NIHAR P,ASHLEY F,et al. Metastatic castration-resistant prostate cancer: critical review of enzalutamide[J]. Clinical Medicine Insights:Oncology,2013(7):235-245.